LUNG CANCER

Lyudmila Bazhenova, MD, presents the case of a 58-year-old woman with ALK+ non–small cell lung cancer.

Alex Spira, MD, PhD, director, Virginia Cancer Specialists, Phase I Trial Program, Fairfax, VA, discussed the use of durvalumab as treatment of a 63-year-old male with unresectable stage III non–small cell lung cancer.

During a virtual Case Based Peer Perspective series, Zofia Piotrowska, MD, discussed the case of a 66-year-old man with non–small cell lung cancer and a genetic mutation.

The case of a 73-year-old Asian patient diagnosed with non–small cell lung cancer and an EGFR exon 19 deletion was discussed during a virtual Case Based Peer Perspectives event, led by Melissa L. Johnson, MD.

The FDA has approved pralsetinib for the treatment of adult patients with metastatic RET fusion–positive non–small cell lung cancer, as detected by an FDA-approved test.

During a virtual Case Based Peer Perspectives event, Mark G. Kris, MD, attending physician, Thoracic Oncology Service, William and Joy Ruane chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discussed molecular testing for a 59-year-old patient with poorly differentiated adenocarcinoma of the lung, as wells as the treatment options for the patient.

In the first reported trial of an immune checkpoint inhibitor with chemotherapy in patients with treatment naïve malignant pleural mesothelioma, durvalumab in combination with cisplatin and pemetrexed demonstrated clinical activity and tolerability, according to published study.

Clinically meaningful antitumor activity was observed with capmatinib in patients with metastatic non–small cell lung cancer who harbor MET exon 14 skipping mutations, according to results from the phase 2 GEOMETRY mono-1 clinical trial.

The survival outcomes observed in this study further supported the biosimilarity between bevacizumab and SB8.

John V. Heymach, MD, PhD, reviewed the case of a 73-year-old women with extensive-stage small cell lung cancer during a virtual Case Based Peer Perspective event.

Edward B. Garon, MD, discusses an exciting new agent, or class of agents, that are under evaluation as treatment of patients with non-small cell lung cancer.